Company record · ARMP · Biological Products, (No Diagnostic Substances)
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc.'s chief financial officer on the record is David House, effective July 17, 2026, per the filing record.
The record holds 1 verified CFO change for Armata Pharmaceuticals, Inc. from Form 8-K filings, filed July 20, 2026 and the CFO signature on its 10-K filed March 25, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | David House |
| Title as printed | Chief Financial Officer |
| Basis | Latest move: appointment, 8-K filed July 20, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-07-20Appointment
Armata Pharmaceuticals, Inc. appoints David House as CFOeffective July 17, 2026 · 8-K filed July 20, 2026 · sec.gov, Item 5.02
2026-03-2510-K signature
David D. House signed the annual report as Senior Vice President, Finance and Principal Financial Officer
10-K filed March 25, 2026 · sec.gov
“/s/ David D. House Senior Vice President, Finance and Principal Financial Officer”
Company
| Ticker | ARMP |
|---|---|
| SEC CIK | 0000921114 |
| Industry (SIC) | Biological Products, (No Diagnostic Substances) (2836) |
| Roster note | The DEF 14A filed 2026-04-27 does not name David D. House near a Chief Financial Officer title; check for a change. An 8-K with Item 5.02 was filed on 2026-07-20, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
Allogene Therapeutics, Inc.ALLO
Departure disclosed · Geoffrey Parker · no successor on the record yet
Atara Biotherapeutics, Inc.ATRA
Interim CFO: Kevin G. Sarney · effective June 26, 2026
Caribou Biosciences, Inc.CRBU
Departure disclosed · Sriram Ryali · no successor on the record yet
ImageneBio, Inc.IMA
CFO: Yanina Grant-Huerta · effective July 20, 2026
IRulya Therapeutics Inc.QNCX
CFO: John Militello · effective not stated in the source
Jasper Therapeutics, Inc.JSPR
Interim CFO: Jeet Mahal · effective October 9, 2026
Kalaris Therapeutics, Inc.KLRS
CFO: Liisa Bayko · effective July 20, 2026
Precision BioSciences, Inc.DTIL
CFO: Naresh Tanna · effective August 1, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.